Takeda's dengue vaccine candidate (TAK-003) prevented 83.6% of hospitalizations and 62.0% of dengue illness overall, with no identified important safety risks through three years following vaccination in ongoing pivotal Phase 3 TIDES trial; Regulatory ...
from Google Alert - health https://ift.tt/3uhO1QG
via IFTTT
0 comments:
Post a Comment